Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Fulcrum Therapeutics, Inc. (FULC)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 63,029,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. Co. has developed a proprietary product engine, FulcrumSeek, that it employs to systematically identify and validate cellular drug targets. Co.' products include: losmapimod, a small molecule that it is developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive and disabling disorder characterized by muscle degeneration and fat infiltration; and FTX-6058, an investigational oral fetal hemoglobin, inducer that is in development for sickle cell disease and select other hemoglobinopathies, including ss-thalassemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 43,360 43,360 43,360 4,472,361
Total Buy Value $492,028 $492,028 $492,028 $39,173,214
Total People Bought 1 1 1 2
Total Buy Transactions 1 1 1 7
Total Shares Sold 5,120 5,120 5,120 150,153
Total Sell Value $59,050 $59,050 $59,050 $1,271,940
Total People Sold 1 1 1 2
Total Sell Transactions 2 2 2 8
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 122
  Page 2 of 5  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Gould Robert J Director   –       •      –    2022-04-04 4 AS $24.02 $173,749 D/D (7,235) 506,630     -
   Gould Robert J Director   –       •      –    2022-04-04 4 OE $7.84 $56,722 D/D 7,235 513,865     -
   Gould Robert J Director   –       •      –    2022-04-01 4 AS $24.03 $828,160 D/D (34,464) 506,630     -
   Gould Robert J Director   –       •      –    2022-04-01 4 OE $7.84 $270,198 D/D 34,464 541,094     -
   Levin Mark J Director   –       •       •   2021-11-10 4 AS $0.00 $0 I/I (1,000,000) 3,962,202     -
   Tepper Robert I 10% Owner   –       –       •   2021-11-10 4 AS $0.00 $0 D/D (1,000,000) 3,962,202     -
   Levin Mark J Director   –       •       •   2021-09-22 4 AS $0.00 $0 I/I (1,000,000) 4,962,202     -
   Tepper Robert I 10% Owner   –       –       •   2021-09-22 4 AS $0.00 $0 D/D (1,000,000) 4,962,202     -
   Stuart Bryan See Remarks   •       •      –    2021-08-11 4 AS $23.75 $665,000 D/D (28,000) 0     -
   Stuart Bryan See Remarks   •       •      –    2021-08-11 4 OE $7.84 $219,520 D/D 28,000 28,000     -
   Moxham Christopher Chief Scientific Officer   •       –      –    2021-08-10 4 AS $17.00 $911,416 D/D (51,785) 0     -
   Moxham Christopher Chief Scientific Officer   •       –      –    2021-08-10 4 OE $7.84 $405,994 D/D 51,785 31,071     -
   Stuart Bryan See Remarks   •       •      –    2021-08-10 4 AS $17.50 $560,000 D/D (32,000) 0     -
   Stuart Bryan See Remarks   •       •      –    2021-08-10 4 OE $7.84 $250,880 D/D 32,000 32,000     -
   Thomson Peter G. VP Finance & Accounting   •       –      –    2021-06-28 4 B $9.00 $20,700 I/I 2,300 2,300 1.99     -
   Geraghty James A Director   –       •      –    2021-06-28 4 B $9.16 $91,600 D/D 10,000 90,714 2.39     -
   Oltmans Curtis Gale SVP, General Counsel   •       –      –    2021-06-28 4 B $9.01 $9,803 D/D 1,088 1,088 2.74     -
   Morabito Christopher Chief Medical Officer   •       –      –    2021-06-28 4 B $9.16 $10,076 D/D 1,100 1,100 2.74     -
   Gould Robert J See Remarks   •       •      –    2021-03-16 4 AS $12.43 $9,806 D/D (789) 506,630     -
   Gould Robert J See Remarks   •       •      –    2021-03-15 4 AS $12.13 $111,773 D/D (9,211) 507,419     -
   Thomson Peter G. VP Finance & Accounting   •       –      –    2021-02-22 4 AS $14.72 $73,582 D/D (5,000) 15,212     -
   Thomson Peter G. VP Finance & Accounting   •       –      –    2021-02-22 4 OE $7.84 $39,200 D/D 5,000 20,212     -
   Gould Robert J See Remarks   •       •      –    2021-02-16 4 AS $14.19 $117,197 D/D (8,215) 516,630     -
   Thomson Peter G. VP Finance & Accounting   •       –      –    2021-01-21 4 AS $14.00 $92,498 D/D (6,607) 15,212     -
   Gould Robert J See Remarks   •       •      –    2021-01-20 4 AS $12.08 $120,826 D/D (10,000) 524,845     -
  122 Records found
  1  2  3  4  5   
  Page 2 of 5
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us